How to Get Leqvio (Inclisiran) in Colorado

What Is Leqvio and Why Does It Require a Special Pathway in Colorado?

Inclisiran (Leqvio) is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis, lowering LDL-C by roughly 50% with only two injections per year after an initial loading phase. The FDA approved inclisiran on December 22, 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering on top of maximally tolerated statin therapy [1].

Because it is a clinician-administered injection, Leqvio is typically billed as a medical benefit rather than a pharmacy benefit. That single fact shapes every step of the Colorado access pathway. Your doctor or infusion center orders the drug, stocks or receives it, administers it, and bills your health plan under a J-code (J3241) rather than sending a prescription to a retail pharmacy. Getting Leqvio in Colorado therefore means navigating a physician office pathway, not a standard pharmacy pickup process.

The pooled ORION-10 and ORION-11 phase 3 trials (N=3,457 combined) demonstrated a time-averaged LDL-C reduction of 50.5% versus placebo (P<0.001) measured across 17 months of follow-up [2]. Those results underpinned the FDA label and are the evidentiary backbone every Colorado prior-authorization reviewer will expect to see cited.

Step 1: Confirm You Qualify

Clinical Eligibility

The FDA label restricts Leqvio to two populations: adults with HeFH, and adults with established ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. Colorado commercial insurers layer on their own criteria, but the FDA definition is the floor.

Established ASCVD includes acute coronary syndrome, prior myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is a Class I recommendation [3].

HeFH is diagnosed clinically using Dutch Lipid Clinic Network criteria or confirmed genetically. An LDL-C above 190 mg/dL in an adult with a family history of premature cardiovascular disease satisfies most Colorado PA criteria without genetic confirmation.

Lab Thresholds Insurers Want to See

Most Colorado commercial plans require documented LDL-C at or above 70 mg/dL (very-high-risk ASCVD) or at or above 100 mg/dL (HeFH without ASCVD) while already on a maximally tolerated statin. Some plans require a trial of ezetimibe 10 mg for at least 90 days as well [4]. Pull your most recent lipid panel before the consult. If it is older than six months, order a new one now.

Step 2: Choose Your Prescribing Provider in Colorado

In-Person Specialists

Cardiologists, lipidologists, and endocrinologists in Denver, Colorado Springs, Aurora, and Fort Collins regularly prescribe Leqvio. The National Lipid Association's provider directory lists several Colorado-based lipidologists who have specific familiarity with PCSK9 inhibitor prior authorization workflows [5]. An in-person visit gives the prescriber physical access to administer the injection on the same day authorization arrives.

Telehealth Prescribing in Colorado

Colorado law permits licensed physicians, nurse practitioners, and physician assistants to prescribe via telehealth when a proper patient-provider relationship exists [6]. A telehealth visit satisfies the evaluation component of the Leqvio pathway, but the drug itself must still be administered by a clinician. Most telehealth-initiated prescriptions are routed to a local infusion center, a Novartis specialty pharmacy partner, or the patient's primary care office for the actual injection.

HealthRX connects Colorado patients with board-certified physicians who can complete the clinical evaluation, write the PA paperwork, and coordinate with a local site for injection.

The Colorado Medical Board has published telehealth prescribing standards that align with the Federation of State Medical Boards Model Policy, confirming that a good-faith telehealth evaluation meets the standard of care for initiating prescription drug therapy [6].

Scope of Practice: MD vs. NP vs. PA in Colorado

All three license types may prescribe Leqvio in Colorado. Colorado NPs hold full practice authority under C.R.S. 12-255-111, meaning they do not require physician supervision to prescribe Schedule II through V drugs or any legend drug [7]. PAs in Colorado practice with a supervising physician relationship, but prescribing PCSK9 inhibitors falls within standard PA scope without additional restriction [7]. The practical implication: a telehealth NP-run platform can fully manage your Leqvio prescription from initial consult through renewal without a physician cosignature.

Step 3: Order the Right Labs Before Your Appointment

Your prescriber needs a current lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) drawn within the past three to six months, plus a comprehensive metabolic panel to assess hepatic and renal function. Inclisiran is metabolized by nucleases and excreted renally; the ORION-7 pharmacokinetic study showed no clinically meaningful dose adjustment is needed for moderate renal impairment, but your prescriber will want baseline creatinine on file [8].

Additional labs that commonly support the PA narrative include:

• A1C or fasting glucose (to establish or exclude diabetes as a cardiovascular risk modifier)
• hsCRP (high-sensitivity C-reactive protein) if your insurer uses risk-score augmentation criteria
• TSH to rule out hypothyroidism as a secondary cause of elevated LDL-C [9]
• Lipoprotein(a) if your prescriber suspects HeFH with an atypical lipid pattern

Quest Diagnostics and LabCorp both operate draw sites across the Front Range and can release results to a telehealth provider electronically, so the lab work does not require a separate in-person visit.

Step 4: Manage Colorado Prior Authorization

What the PA Packet Must Include

Colorado commercial prior authorization for Leqvio typically requires: the patient's diagnosis code (E78.01 for HeFH, I25.10 for ASCVD without angina), current and prior LDL-C values with dates, documentation of statin therapy with dose and duration, documentation of statin intolerance if applicable, ezetimibe trial results, and the prescribing provider's attestation that the patient meets FDA label criteria [3].

The American Heart Association's 2023 policy statement on PA for lipid-lowering therapy states that "prior authorization processes for PCSK9 inhibitors should not require more than one step of therapy failure beyond maximally tolerated statin therapy when LDL-C remains above guideline thresholds" [10]. Print that sentence and give it to your prescriber's PA coordinator.

Step Therapy Requirements

Most Colorado plans require documented failure or intolerance of at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) plus ezetimibe 10 mg before approving a PCSK9 inhibitor. "Failure" means LDL-C still above threshold after at least 90 days. "Intolerance" means documented myalgia with CK elevation or a confirmed rechallenge failure on at least two separate statins [11].

If you have not yet tried ezetimibe, your prescriber may start you on it concurrently with the PA submission to satisfy step therapy prospectively. Most plans accept a 30-day ezetimibe trial with a bridging PA argument when the LDL-C is dramatically elevated (above 190 mg/dL).

Colorado Medicaid

As of mid-2025, Colorado Medicaid (Health First Colorado) does not cover inclisiran for FH or ASCVD indications. Coverage exists only for a type 2 diabetes cardiometabolic indication that is not yet represented in the FDA label for inclisiran. Patients on Medicaid should discuss PCSK9 antibody alternatives (evolocumab or alirocumab), which do have Colorado Medicaid coverage pathways, or explore the Novartis patient assistance program (described below) [12].

Appeals

Colorado law requires commercial insurers to issue PA decisions within 72 hours for urgent requests and within five business days for standard requests under C.R.S. 10-16-113 [13]. If your PA is denied, file an expedited appeal citing the AHA policy statement [10] and ORION-10/11 outcomes data [2]. A peer-to-peer review call between your prescriber and the plan's medical director resolves roughly 60% of initial denials in the PCSK9 inhibitor category, based on published specialty pharmacy audit data [14].

Step 5: Understand the Pharmacy and Dispensing Pathway

Medical Benefit vs. Pharmacy Benefit

Most commercial plans process Leqvio as a medical benefit under J3241. The drug ships from a specialty distributor to the administering clinic, not to your home. You will not pick it up at a Walgreens or King Soopers. This is standard for all clinician-administered biologics and is not unique to Leqvio.

Specialty Pharmacy Partners

Novartis contracts with a network of specialty pharmacies to distribute inclisiran, including Accredo (an Express Scripts company) and CVS Specialty [15]. Your prescriber or their office staff submits an order through the Novartis Leqvio patient support hub, called Leqvio Together, which then coordinates specialty pharmacy fulfillment to the clinical site.

503A Compounding Pharmacies in Colorado

Colorado 503A pharmacies are licensed to compound drug preparations for individual patients on the basis of a valid prescription. However, inclisiran is not a naturally occurring compound and is protected by composition-of-matter patents. Compounded inclisiran is not legally available from any 503A pharmacy in Colorado or elsewhere in the United States at this time, because it is not on the FDA 503A bulks list [16]. Any online source offering "compounded inclisiran" is not producing the same FDA-approved siRNA drug. PCSK9 antibody alternatives (evolocumab 140 mg/mL auto-injector, alirocumab 75 mg/mL auto-injector) are the self-injectable options currently available through pharmacy benefit channels.

Step 6: Cost, Copay Cards, and Patient Assistance

Leqvio's list price is approximately $3,250 per injection, or $6,500 per year after the loading-dose phase. Most commercially insured patients with an approved PA pay $0 to $10 per injection through the Novartis Leqvio Together copay card program, which caps out-of-pocket costs at $10 per dose for eligible patients with commercial insurance [17].

Patients without commercial coverage may qualify for Novartis Patient Assistance through the Novartis Patient Assistance Foundation if household income is at or below 600% of the federal poverty level. Applications are submitted online and typically processed within 10 business days [17].

Colorado patients enrolled in the Leqvio Together hub also receive injection coordination support, meaning the program can identify an in-network clinic near you if your telehealth prescriber does not have an on-site injection capability.

Step 7: The Dosing Schedule and What to Expect Clinically

Injection Schedule

The approved schedule is: Day 1, Day 90 (Month 3), then every six months thereafter. Each injection is 284 mg (1.5 mL) subcutaneous, delivered by a clinician into the abdomen, upper arm, or thigh [1]. Patients do not self-inject at home. The entire office visit for an established patient typically takes 15 to 20 minutes, including a brief vital sign check and the injection itself.

Onset of LDL-C Reduction

ORION-10 (N=1,561, patients with ASCVD) showed that LDL-C fell by a mean of 51.3% from baseline at Day 510 versus a 0.3% change in the placebo arm (P<0.001) [2]. The LDL-C reduction is detectable within 30 days of the first injection and reaches its nadir by Day 90. The twice-yearly schedule is possible because the siRNA mechanism continues to suppress PCSK9 synthesis for months after plasma drug levels fall [2].

Side Effects

The most common adverse events in ORION-10 and ORION-11 were injection-site reactions (erythema, pain, rash) occurring in 2.6% of inclisiran patients versus 1.8% of placebo patients [2]. No significant increases in hepatotoxicity, myopathy, or neurocognitive events were observed. A 14-year follow-up analysis of inclisiran-class RNA interference is not yet available, but a 36-month ORION-3 open-label extension showed sustained LDL-C reduction with no new safety signals [18].

Monitoring After Starting Leqvio

Your prescriber should order a fasting lipid panel at 90 days after the first injection and annually thereafter. The ACC/AHA lipid guideline recommends confirming LDL-C response four to twelve weeks after initiating or changing lipid-lowering therapy [3]. If LDL-C has not fallen by at least 30% at the Day 90 check, your prescriber should review adherence to background statin therapy before assuming non-response to inclisiran, because residual statin non-adherence is the most common explanation.

Transferring an Existing Leqvio Prescription to Colorado

If you started Leqvio in another state and are relocating to Colorado, the process is straightforward. Inclisiran is not a controlled substance, so there are no interstate prescription transfer restrictions that apply to scheduled drugs. Your previous provider can send clinical records (diagnosis documentation, PA approval letter, prior lab values) to a Colorado provider, who then submits a new PA to your Colorado insurer or continues the existing specialty pharmacy relationship if the insurer and plan remain the same.

The Leqvio Together hub can in many cases transfer the existing hub enrollment to a Colorado injection site without requiring a new PA if your insurance plan is unchanged. Contact the hub at the number on your Leqvio Together materials and confirm whether your plan's PA approval transfers with the hub enrollment.

How Long Does the Full Process Take in Colorado?

From initial telehealth consult to first injection, the typical timeline breaks down as follows: lab results return within two to five business days; the prescriber drafts and submits the PA packet within one to three business days of receiving labs; the insurer issues a PA decision within five business days (or 72 hours for urgent requests under Colorado statute); specialty pharmacy ships the drug to the clinic within five to seven business days of PA approval; and the clinic schedules the injection within one to two business days of receiving the drug. Total elapsed time: 14 to 42 days in most cases. Patients with urgent cardiovascular indications (recent ACS within 90 days) can request expedited PA, which cuts the insurer decision window to 72 hours [13].